ClinicalTrials.gg
Active, not recruitingNCT03737643DUO-OUpdated Jul 7, 2026Results posted

Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients

A Phase 3 interventional study of Bevacizumab and Durvalumab in Advanced Ovarian Cancer, sponsored by AstraZeneca. Active, not recruiting at 214 sites in 20 countries. Open to female participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2026-07-07.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,407
Allocation
Randomized
Ages
18 Years to 130 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 14 studies testing durvalumab in Ovarian Neoplasms — 2 open to participants now, 6 under way, 1 of them phase 3. durvalumab · Ovarian Neoplasms.

Enrollment
Largest of 14
1,407 · median 85
Started
2019
the only one that year
Phase 3
Only one
of the 14
Registered
11th of 14
by date
Lead sponsor
4 of 14
AstraZeneca

Among the 14 studies testing durvalumab in Ovarian Neoplasms, this one has the largest enrollment, is the only one that started in 2019, is the only one in phase 3, and was the 11th registered.

Ovarian Neoplasms

3,387 studies on the registry are indexed under Ovarian Neoplasms; 792 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

2 of the 14 studies testing durvalumab in Ovarian Neoplasms are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About durvalumab

durvalumab: first FDA approval 2017 (IMFINZI), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 605 Ovarian Neoplasms studies recruiting now, 442 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.

This study: 18 Years to 130 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing durvalumab in Ovarian Neoplasms, or all of them as a file.
02

Study summary

This is a Phase III randomised, double-blind, multi-centre study to evaluate the efficacy and safety of durvalumab in combination with standard of care platinum based chemotherapy and bevacizumab followed by maintenance durvalumab and bevacizumab or durvalumab, bevacizumab and olaparib in patients with newly diagnosed advanced ovarian cancer.

Read the detailed description

Eligible patients will be those patients with newly diagnosed, histologically confirmed advanced (Fédération Internationale de Gynécologie et d'Obstétrique [FIGO] Stage III-IV) ovarian, primary peritoneal cancer and/or fallopian-tube cancer. All patients should be candidates for cytoreductive surgery which could be conducted as immediate upfront primary surgery following diagnosis or can be conducted after initiation of platinum based neoadjuvant chemotherapy. All patients should be eligible to start first line platinum based chemotherapy in combination with bevacizumab.

The study aims to evaluate the efficacy and safety of standard of care (SoC) platinum-based chemotherapy and bevacizumab followed by maintenance bevacizumab either as monotherapy, or in combination with durvalumab, or in combination with durvalumab and olaparib. Therefore, this study aims to see which combination allows patients to live longer without the cancer coming back or getting worse. The study is also looking to see which combination makes patients live longer and how the treatment and the cancer affects their quality of life.

03

Conditions studied

  • Advanced Ovarian Cancer

Browse trials for

Keywords

  • Advanced Ovarian Cancer
  • Ovarian neoplasms
04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

Female patients with newly diagnosed, confirmed, advanced (Stage III-IV) high grade epithelial ovarian cancer including high grade serious, high grade endometriod, clear cell ovarian cancer or carcinosarcoma, primary peritoneal cancer and / or fallopian-tube cancer

  • Patients must be aged ≥18 years of age. For patients enrolled in Japan that are aged \<20 year
  • All patients should be candidates for cytoreductive surgery either: upfront primary surgery OR plan to undergo chemotherapy with interval debulking surgery
  • Evidence of presence or absence of BRCA1/2 mutation in tumour tissue
  • Mandatory provision of tumour sample for centralised tBRCA testing
  • performance status 0-1
  • Patients must have preserved organ and bone marrow function
  • or evidence of non-childbearing status for women of : negative urine or serum pregnancy test

Key Exclusion Criteria:

Non-epithelial ovarian cancer, borderline tumors, low grade epithelial tumors or mucinous histology

  • Prior systemic anti-cancer therapy for ovarian cancer
  • Inability to determine the presence or absence of a deleterious or suspected deleterious BRCA mutation
  • Prior treatment with PARP inhibitor or immune mediated therapy
  • Planned intraperitoneal cytotoxic chemotherapy
  • Active or prior documented or inflammatory disorders
  • Patients considered a poor medical risk due to a serious, uncontrolled intercurrent illness
  • cardiovascular disease
  • Patients with known
  • History of another primary except for:

    • Malignancy treated with curative intent and with no known active disease ≥5 years before the first dose of study treatment and of low potential risk for recurrence (patients who have received prior chemotherapy for early stage breast cancer may be eligible, provided that it was completed ≥3 years prior to registration, and that the patient remains free of recurrent or disease)
    • Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease
    • Adequately treated carcinoma in situ without evidence of disease
    • Endometrial cancer FIGO Stage IA, Grade 1 or Grade 2
  • Persistent toxicities Grade >2 caused by previous cancer therapy
  • Patients with a known to olaparib, durvalumab or any of the of these products and to the combination/comparator agents
  • Breast feeding women
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,407 participants (actual)

Study arms

  • Active comparator
    Arm 1

    Platinum-based chemotherapy in combination with bevacizumab and durvalumab placebo (saline IV infusion) followed by maintenance bevacizumab, durvalumab placebo (saline IV infusion) and olaparib placebo (tablets).

    Drug: Bevacizumab · Drug: Placebo olaparib · Drug: Durvalumab placebo · Drug: Carboplatin+Paclitaxel

  • Experimental
    Arm 2

    Platinum-based chemotherapy in combination with bevacizumab and durvalumab followed by maintenance bevacizumab, durvalumab and olaparib placebo.

    Drug: Bevacizumab · Drug: Durvalumab · Drug: Placebo olaparib · Drug: Carboplatin+Paclitaxel

  • Experimental
    Arm 3

    Platinum-based chemotherapy in combination with bevacizumab and durvalumab followed by maintenance bevacizumab, durvalumab and olaparib.

    Drug: Bevacizumab · Drug: Durvalumab · Drug: Olaparib · Drug: Carboplatin+Paclitaxel

  • Experimental
    tBRCAm cohort

    Platinum-based chemotherapy in combination with bevacizumab and durvalumab followed by maintenance bevacizumab, durvalumab and olaparib. Bevacizumab is optional according to local practice.

    Drug: Bevacizumab · Drug: Durvalumab · Drug: Olaparib · Drug: Carboplatin+Paclitaxel

Interventions

  • Bevacizumab by intravenous infusion. In tBRCAm cohort bevacizumab is optional according to local practice.

  • Durvalumab by intravenous infusion

  • Olaparib tablets

  • DrugPlacebo olaparib

    Placebo tablets to match olaparib

  • DrugDurvalumab placebo

    Matching placebo for intravenous infusion

  • DrugCarboplatin+Paclitaxel

    Drug pages: Carboplatin · Paclitaxel

    Standard of care chemotherapy

06

What researchers measure

Primary outcomes

  1. Progression-free Survival (PFS) by Investigator Assessment Using Modified RECIST 1.1 - Full Analysis Set

    To determine the efficacy of durvalumab in combination with platinum based chemotherapy and bevacizumab and continued as maintenance in combination with bevacizumab and olaparib versus SoC platinum based chemotherapy in combination with bevacizumab by assessment of PFS (using investigator assessment according to Response Evaluation Criteria in Solid Tumours version 1.1 \[RECIST 1.1\]) in the first line treatment of patients with newly diagnosed advanced ovarian cancer. Per MTP, the comparison of SoC+D+O v SoC in the Non-tbRCAm patients is a primary endpoint. SoC+D v SoC is reported separately as a secondary endpoint. Results for tBRCAm SoC+D+O are not presented as this was prespecified to be assessed only in the Non-tBRCAm patients.

    Time frame: At baseline, within 3 weeks of last dose of chemotherapy, then every 12 weeks for 3 years and thereafter every 24 weeks. Assessed until primary analysis - (05DEC2022 for Global cohort, 17MAR2025 for China cohort) - upto 46 months

  2. Progression-free Survival (PFS) by Investigator Assessment Using Modified RECIST 1.1 - (Full Analysis Set, HRD Positive)

    To determine the efficacy of durvalumab and olaparib assessed by PFS in the first line treatment of patients with newly diagnosed advanced ovarian cancer. Per MTP, the comparison of SoC+D+O v SoC in the Non-tBRCAm HRD positve population is a primary endpoint. SoC+D v SoC is reported separately as a secondary endpoint. Results for tBRCAm SoC+D+O are not presented as as this was prespecified to be assessed only in the Non-tBRCAm patients.

    Time frame: At baseline, within 3 weeks of last dose of chemotherapy, then every 12 weeks for 3 years and thereafter every 24 weeks. Assessed until DCO1 - (05DEC2022 for Global cohort, 17MAR2025 for China cohort) - upto 46 months

Secondary outcomes

  1. Progression-free Survival (PFS) by Investigator Assessment Using Modified RECIST 1.1 - Full Analysis Set

    To determine the efficacy of durvalumab assessed by PFS in the first line treatment of patients with newly diagnosed advanced ovarian cancer. Per MTP, the comparison of SoC+D v SoC is a secondary endpoint. SoC+D+O v SoC is reported separately as a primary endpoint. Results for tBRCAm SoC+D+O are not presented as this was prespecified to be assessed only in the Non-tBRCAm patients.

    Time frame: At baseline, within 3 weeks of last dose of chemotherapy, then every 12 weeks for 3 years and thereafter every 24 weeks. For global cohort, assessed until DCO2 (18SEP2023) - up to 55 months. For China cohort assessed until DCO1 (17MAR2025) - 46 months.

  2. Overall Survival - Full Analysis Set

    To determine the efficacy of durvalumab and olaparib assessed by OS in the first line treatment patients with newly diagnosed advanced ovarian cancer. Overall survival (OS) is defined as the time from randomisation/allocation to death due to any cause regardless of whether the patient withdraws from randomised therapy or receives another anti-cancer therapy. Results for tBRCAm SoC+D+O are not presented as this was prespecified to be assessed only in the Non-tBRCAm patients.

    Time frame: Survival assessed every 12 weeks after RECIST 1.1 defined progression. For global cohort, assessed until DCO3 (17MAR2025) - up to 73 months. For China cohort assessed until DCO1 (17MAR2025) - up to 46 months.

  3. Overall Survival - (Full Analysis Set, HRD-positive)

    To determine the efficacy of durvalumab and olaparib assessed by OS in the first line treatment patients with newly diagnosed advanced ovarian cancer. Overall survival (OS) is defined as the time from randomisation/allocation to death due to any cause regardless of whether the patient withdraws from randomised therapy or receives another anti-cancer therapy. Results for tBRCAm SoC+D+O are not presented as this was prespecified to be assessed only in the Non-tBRCAm patients.

    Time frame: Survival assessed every 12 weeks after RECIST 1.1 defined progression. For global cohort, assessed until DCO3 (17MAR2025) - up to 73 months. For China cohort assessed until DCO1 (17MAR2025) - up to 46 months.

  4. Time to Second Progression or Death Based on Local Standard Clinical Practice (PFS2) - Full Analysis Set

    To assess the efficacy of durvalumab and olaparib in terms of PFS2 in the first line treatment of patients with newly diagnosed advanced ovarian cancer. Time to second progression or death (PFS2) is defined as the time from the date of randomisation/allocation to the earliest of the progression event subsequent to first subsequent therapy or death. Results for tBRCAm SoC+D+O are not presented as this was prespecified to be assessed only in the Non-tBRCAm patients.

    Time frame: Assessed every 12 weeks after RECIST 1.1 defined progression. For global cohort, assessed until DCO3 (17MAR2025) - up to 73 months. For China cohort assessed until DCO1 (17MAR2025) - 46 months.

  5. Time to Second Progression or Death Based on Local Standard Clinical Practice (PFS2) - (Full Analysis Set, HRD-positive)

    To assess the efficacy of durvalumab and olaparib in terms of PFS2 in the first line treatment of patients with newly diagnosed advanced ovarian cancer. Time to second progression or death (PFS2) is defined as the time from the date of randomisation/allocation to the earliest of the progression event subsequent to first subsequent therapy or death. Results for tBRCAm SoC+D+O are not presented as this was prespecified to be assessed only in the Non-tBRCAm patients.

    Time frame: Assessed every 12 weeks after RECIST 1.1 defined progression. For global cohort, assessed until DCO3 (17MAR2025) - up to 73 months. For China cohort assessed until DCO1 (17MAR2025) - 46 months.

  6. Objective Response Rate Based on Investigator Assessment (Full Analysis Set)

    To assess the efficacy of durvalumab and olaparib in terms of ORR (Complete Response + Partial Response) by investigator assessment by modified RECIST 1.1: 1. in all patients with evaluable disease at baseline 2. prior to surgery in those patients planned to have IDS with evaluable disease at baseline. Objective response rate (ORR) is defined similarly for the non-tBRCAm and tBRCAm cohorts as the number (percentage) of patients with at least one investigator-assessed visit response of CR or PR and will be based on a subset of all randomised/allocated patients who have evaluable disease at baseline per the site investigator.

    Time frame: At baseline, within 3 weeks of last dose of chemotherapy, then every 12 weeks for 3 years and thereafter every 24 weeks. Up to 55 months for global non-tBRCAm (DCO2 18SEP2023). Up to 46 for Global tBRCAm (DCO1 05DEC2022) and China (DCO1 17MAR2025)

  7. Objective Response Rate Based on Investigator Assessment (Full Analysis Set, HRD-positive)

    To assess the efficacy of durvalumab and olaparib in terms of ORR (Complete Response + Partial Response) by investigator assessment by modified RECIST 1.1 1. in all patients with evaluable disease at baseline 2. prior to surgery in those patients planned to have IDS with evaluable disease at baseline. Objective response rate (ORR) is defined similarly for the non-tBRCAm and tBRCAm cohorts as the number (percentage) of patients with at least one investigator-assessed visit response of CR or PR and will be based on a subset of all randomised/allocated patients who have evaluable disease at baseline per the site investigator. This was prespecified to be assessed only in the non-tBRCAm cohort.

    Time frame: At baseline, within 3 weeks of last dose of chemotherapy, then every 12 weeks for 3 years and thereafter every 24 weeks. Up to 55 months for global non-tBRCAm (DCO2 18SEP2023). Up to 46 for China (DCO1 17MAR2025)

  8. Duration of Objective Response Based on Investigator Assessments (Full Analysis Set)

    To assess the efficacy of durvalumab and olaparib in terms of duration of response (DoR) in the first line treatment of patients with newly diagnosed advanced ovarian cancer. Duration of response (DoR) is defined similarly for the non-tBRCAm and tBRCAm cohorts using the corresponding FAS among patients with a response (CR or PR), as the time from the date of first documented response (i.e., the first time at which the visit response is PR or CR) according to modified RECIST v1.1 as assessed by the investigator until date of documented progression or death in the absence of disease progression. This was prespecified to be assessed only in the Global patients.

    Time frame: At baseline, within 3 weeks of last dose of chemotherapy, then every 12 weeks for 3 years and thereafter every 24 weeks. Up to 55 months for global non-tBRCAm (DCO2 18SEP2023). Up to 46 for Global tBRCAm (DCO1 05DEC2022)

  9. Duration of Objective Response Based on Investigator Assessments (Full Analysis Set, HRD-positive)

    To assess the efficacy of durvalumab and olaparib in terms of duration of response (DoR) in the first line treatment of patients with newly diagnosed advanced ovarian cancer. Duration of response (DoR) is defined similarly for the non-tBRCAm and tBRCAm cohorts using the corresponding FAS among patients with a response (CR or PR), as the time from the date of first documented response (i.e., the first time at which the visit response is PR or CR) according to modified RECIST v1.1 as assessed by the investigator until date of documented progression or death in the absence of disease progression. This was prespecified to be assessed only in Global Non-tBRCAm patients.

    Time frame: At baseline, within 3 weeks of last dose of chemotherapy, then every 12 weeks for 3 years and thereafter every 24 weeks. Up to 55 months for global non-tBRCAm (DCO2 18SEP2023).

  10. Time to First Subsequent Therapy (TFST) - Full Analysis Set

    To assess the efficacy of durvalumab and olaparib in terms of TFST in the first line treatment of patients with newly diagnosed advanced ovarian cancer. Time to start of first subsequent therapy or death (TFST) is defined as the time from randomisation/allocation to the earlier of first subsequent therapy start date following study treatment discontinuation, or death. This was prespecified to be assessed only in Non-tBRCAm patients.

    Time frame: Assessed every 12 weeks following treatment discontinuation. For global cohort, assessed until DCO3 (17MAR2025) - up to 73 months. For China cohort assessed until DCO1 (17MAR2025) - up to 46 months.

  11. Time to First Subsequent Therapy (TFST) - (Full Analysis Set, HRD-positive)

    To assess the efficacy of durvalumab and olaparib in terms of TFST in the first line treatment of patients with newly diagnosed advanced ovarian cancer. Time to start of first subsequent therapy or death (TFST) is defined as the time from randomisation/allocation to the earlier of first subsequent therapy start date following study treatment discontinuation, or death. This was prespecified to be assessed only in Non-tBRCAm patients.

    Time frame: Assessed every 12 weeks following treatment discontinuation. For global cohort, assessed until DCO3 (17MAR2025) - up to 73 months. For China cohort assessed until DCO1 (17MAR2025) - up to 46 months.

  12. Time to Second Subsequent Therapy (TSST) - Full Analysis Set

    To assess the efficacy of durvalumab and olaparib in terms of TSST in the first line treatment of patients with newly diagnosed advanced ovarian cancer. Time to second subsequent therapy or death (TSST) is defined as the time from randomisation/allocation to the earlier of the second subsequent anti-cancer therapy start date following study treatment discontinuation, or death. This was prespecified to be assessed only in Non-tBRCAm patients.

    Time frame: Assessed every 12 weeks following treatment discontinuation. For global cohort, assessed until DCO3 (17MAR2025) - up to 73 months. For China cohort assessed until DCO1 (17MAR2025) - up to 46 months.

  13. Time to Second Subsequent Therapy (TSST) - (Full Analysis Set, HRD-positive)

    To assess the efficacy of durvalumab and olaparib in terms of TSST in the first line treatment of patients with newly diagnosed advanced ovarian cancer. Time to second subsequent therapy or death (TSST) is defined as the time from randomisation to the earlier of the second subsequent anti-cancer therapy start date following study treatment discontinuation, or death. This was prespecified to be assessed only in Non-tBRCAm patients.

    Time frame: Assessed every 12 weeks following treatment discontinuation. For global cohort, assessed until DCO3 (17MAR2025) - up to 73 months. For China cohort assessed until DCO1 (17MAR2025) - up to 46 months.

  14. Time to Treatment Discontinuation (TDT) - Full Analysis Set

    To assess the efficacy of durvalumab and olaparib in terms of TDT in the first line treatment of patients with newly diagnosed advanced ovarian cancer. Time to permanent study treatment discontinuation or death (TDT) is defined as the time from randomisation/allocation to the earlier of the date of permanent study treatment discontinuation or death. This was prespecified to be assessed only in Non-tBRCAm patients.

    Time frame: Assessed through study completion, up to 73 months for global non-tBRCAm (DCO3 17MAR2025) and up to 46 months for and China (DCO1 17MAR2025)

  15. Time to Treatment Discontinuation (TDT) - (Full Analysis Set, HRD-positive)

    To assess the efficacy of durvalumab and olaparib in terms of TDT in the first line treatment of patients with newly diagnosed advanced ovarian cancer. Time to permanent study treatment discontinuation or death (TDT) is defined as the time from randomisation/allocation to the earlier of the date of permanent study treatment discontinuation or death. This was prespecified to be assessed only in Non-tBRCAm patients.

    Time frame: Assessed through study completion, up to 73 months for global non-tBRCAm (DCO3 17MAR2025) and up to 46 months for and China (DCO1 17MAR2025)

  16. Change From Baseline in Physical Function Score of the EORTC-QLQ-C30 and EORTC-QLQ-OV28 Questionnaires - Full Analysis Set

    To determine the effects on HRQoL, global health status and ovarian cancer symptoms of the combination of durvalumab and olaparib in the first line treatment of non-tBRCAm patients with newly diagnosed advanced ovarian cancer. The physical functioning score is a score from 0 to 100. Higher scores on the physical functioning score indicate better health status/function. This was prespecified to be assessed only in Global Non-tBRCAm patients.

    Time frame: Assessed at week 96.

  17. Change From Baseline in Physical Function Score of the EORTC-QLQ-C30 and EORTC-QLQ-OV28 Questionnaires - (Full Analysis Set, HRD Positive)

    To determine the effects on HRQoL, global health status and ovarian cancer symptoms of the combination of durvalumab and olaparib in the first line treatment of non-tBRCAm patients with newly diagnosed advanced ovarian cancer. The physical functioning score is a score from 0 to 100. Higher scores on the physical functioning score indicate better health status/function. This was prespecified to be assessed only in Global Non-tBRCAm patients.

    Time frame: Assessed at week 96.

  18. Change From Baseline in Global Health Status/QoL Score of the EORTC-QLQ-C30 and EORTC-QLQ-OV28 Questionnaires - Full Analysis Set

    To determine the effects on HRQoL, global health status and ovarian cancer symptoms of the combination of durvalumab and olaparib in the first line treatment of non-tBRCAm patients with newly diagnosed advanced ovarian cancer. The global health status/quality of life (QoL) is a score from 0 to 100. Higher scores on the global health status/QoL indicate better health status/function. This was prespecified to be assessed only in Global Non-tBRCAm patients.

    Time frame: Assessed at week 96.

  19. Change From Baseline in Global Health Status/QoL Score of the EORTC-QLQ-C30 and EORTC-QLQ-OV28 Questionnaires - (Full Analysis Set, HRD Positive)

    To determine the effects on HRQoL, global health status and ovarian cancer symptoms of the combination of durvalumab and olaparib in the first line treatment of non-tBRCAm patients with newly diagnosed advanced ovarian cancer. The global health status/quality of life (QoL) is a score from 0 to 100. Higher scores on the global health status/QoL indicate better health status/function. This was prespecified to be assessed only in Global Non-tBRCAm patients.

    Time frame: Assessed at week 96

  20. Summary of Serum Concentrations (μg/mL) of Durvalumab for Each Treatment - Non-tBRCAm Cohort With Primary Cytoreductive Surgery (Pharmacokinetic Analysis Set)

    To characterize the PK of durvalumab in combination with bevacizumab and olaparib. This was prespecified to be assessed only in Global Non-tBRCAm patients.

    Time frame: Assessed at Day 85 pre-dose, Day 183 pre-dose and 3 months after last dose of durvalumab.

  21. Summary of Plasma Concentrations (μg/mL) of Olaparib - Non-tBRCAm Cohort With Primary Cytoreductive Surgery (Pharmacokinetic Analysis Set)

    To determine olaparib plasma concentrations via sparse sampling for population PK analyses. This was prespecified to be assessed only in Global Non-tBRCAm patients.

    Time frame: Assessed on Day 148 post-dose (1-3 hours, 3-6 hours and 6-12 hours)

  22. Summary of ADA Responses During the Study for Durvalumab - Non-tBRCAm Cohort With Primary Cytoreductive Surgery (ADA Analysis Set)

    To characterize the immunogenicity of durvalumab in combination with bevacizumab and olaparib. This was prespecified to be assessed only in Global Non-tBRCAm patients.

    Time frame: Assessed pre-infusion at Cycle 2, Cycle 4, Cycle 6 and the third cycle of the maintenance phase as well as 3 months after last dose of durvalumab

07

Results

Posted Jun 9, 2026

Participant flow

Overall, 1407 patients were randomised into the study. Global Cohort: 1502 patients screened across 179 sites in 20 countries. 1130 were randomised in the Non-tBRCAm cohort and 154 allocated to the tBRCAm cohort. China Cohort: 134 patients screened across 29 sites; 124 were randomized. 1 patient in the China cohort was randomised prior to Global recruitment closure and hence included in both the Global and China cohort summaries. No patients in the tBRCAm cohort were enrolled from China

Participant flow — Overall Study
MilestoneGlobal Non-tBRCAm: SoCGlobal Non-tBRCAm: SoC + DurvalumabGlobal Non-tBRCAm: SoC + Durvalumab + OlaparibGlobal tBRCAm: SoC + Durvalumab + OlaparibChina Non-tBRCAm: SoCChina Non-tBRCAm: SoC + DurvalumabChina Non-tBRCAm: SoC + Durvalumab + Olaparib
Started378374378154404341
Completed153160172100263134
Not completed2252142065414127
Withdrew: Death2011961864614117
Withdrew: Withdrawal by subject2217207010
Withdrew: Pre-mature site closure and screen failure,2101000

Outcome measures

SecondaryProgression-free Survival (PFS) by Investigator Assessment Using Modified RECIST 1.1 - Full Analysis Set

To determine the efficacy of durvalumab assessed by PFS in the first line treatment of patients with newly diagnosed advanced ovarian cancer. Per MTP, the comparison of SoC+D v SoC is a secondary endpoint. SoC+D+O v SoC is reported separately as a primary endpoint. Results for tBRCAm SoC+D+O are not presented as this was prespecified to be assessed only in the Non-tBRCAm patients.

Time frame:
At baseline, within 3 weeks of last dose of chemotherapy, then every 12 weeks for 3 years and thereafter every 24 weeks. For global cohort, assessed until DCO2 (18SEP2023) - up to 55 months. For China cohort assessed until DCO1 (17MAR2025) - 46 months.
Reported as:
Median · Months
Progression-free Survival (PFS) by Investigator Assessment Using Modified RECIST 1.1 - Full Analysis Set
MonthsGlobal Non-tBRCAm: SoCGlobal Non-tBRCAm: SoC+DChina Non-tBRCAm: SoCChina Non-tBRCAm: SoC+D
Progression-free Survival (PFS) by Investigator Assessment Using Modified RECIST 1.1 - Full Analysis Set19.3 (17.9 to 20.4)20.6 (18.7 to 22.5)17.4 (11.7 to 26.4)21.7 (12.4 to NA)
Statistical analysis
  • Global Non-tBRCAm: SoC vs Global Non-tBRCAm: SoC+D · Log Rank · p = 0.1133 · Hazard ratio (hr): 0.87 · 95% CI 0.74 to 1.03A HR less than 1 favours SoC+D
  • China Non-tBRCAm: SoC vs China Non-tBRCAm: SoC+D · Hazard ratio (hr): 0.80 · 95% CI 0.45 to 1.40A HR less than 1 favours SoC+D
SecondaryOverall Survival - Full Analysis Set

To determine the efficacy of durvalumab and olaparib assessed by OS in the first line treatment patients with newly diagnosed advanced ovarian cancer. Overall survival (OS) is defined as the time from randomisation/allocation to death due to any cause regardless of whether the patient withdraws from randomised therapy or receives another anti-cancer therapy. Results for tBRCAm SoC+D+O are not presented as this was prespecified to be assessed only in the Non-tBRCAm patients.

Time frame:
Survival assessed every 12 weeks after RECIST 1.1 defined progression. For global cohort, assessed until DCO3 (17MAR2025) - up to 73 months. For China cohort assessed until DCO1 (17MAR2025) - up to 46 months.
Reported as:
Median · Months
Overall Survival - Full Analysis Set
MonthsGlobal Non-tBRCAm: SoCGlobal Non-tBRCAm: SoC+DGlobal Non-tBRCAm: SoC+D+OChina Non-tBRCAm: SoCChina Non-tBRCAm: SoC+DChina Non-tBRCAm: SoC+D+O
Overall Survival - Full Analysis Set49.6 (45.8 to 57.8)48.5 (43.6 to 59.0)50.5 (45.2 to 65.1)NA (NA to NA)43.2 (34.1 to NA)NA (NA to NA)
Statistical analysis
  • Global Non-tBRCAm: SoC vs Global Non-tBRCAm: SoC+D+O · Log Rank · p = 0.3781 · Hazard ratio (hr): 0.92 · 95% CI 0.75 to 1.11A HR less than 1 favours SoC+D+O
  • Global Non-tBRCAm: SoC vs Global Non-tBRCAm: SoC+D · Hazard ratio (hr): 0.97 · 95% CI 0.80 to 1.18A HR less than 1 favours SoC+D
  • China Non-tBRCAm: SoC vs China Non-tBRCAm: SoC+D+O · Hazard ratio (hr): 0.42 · 95% CI 0.16 to 1.00A HR less than 1 favours SoC+D+O
  • China Non-tBRCAm: SoC vs China Non-tBRCAm: SoC+D · Hazard ratio (hr): 0.70 · 95% CI 0.31 to 1.53A HR less than 1 favours SoC+D
SecondaryOverall Survival - (Full Analysis Set, HRD-positive)

To determine the efficacy of durvalumab and olaparib assessed by OS in the first line treatment patients with newly diagnosed advanced ovarian cancer. Overall survival (OS) is defined as the time from randomisation/allocation to death due to any cause regardless of whether the patient withdraws from randomised therapy or receives another anti-cancer therapy. Results for tBRCAm SoC+D+O are not presented as this was prespecified to be assessed only in the Non-tBRCAm patients.

Time frame:
Survival assessed every 12 weeks after RECIST 1.1 defined progression. For global cohort, assessed until DCO3 (17MAR2025) - up to 73 months. For China cohort assessed until DCO1 (17MAR2025) - up to 46 months.
Reported as:
Median · Months
Overall Survival - (Full Analysis Set, HRD-positive)
MonthsGlobal Non-tBRCAm: SoCGlobal Non-tBRCAm: SoC+DGlobal Non-tBRCAm: SoC+D+OChina Non-tBRCAm: SoCChina Non-tBRCAm: SoC+DChina Non-tBRCAm: SoC+D+O
Overall Survival - (Full Analysis Set, HRD-positive)66.8 (60.9 to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)
Statistical analysis
  • Global Non-tBRCAm: SoC vs Global Non-tBRCAm: SoC+D+O · Hazard ratio (hr): 0.80 · 95% CI 0.54 to 1.18A HR less than 1 favours SoC+D+O
  • China Non-tBRCAm: SoC vs China Non-tBRCAm: SoC+D+O · Hazard ratio (hr): 0.41 · 95% CI 0.12 to 1.30A HR less than 1 favours SoC+D+O
SecondaryTime to Second Progression or Death Based on Local Standard Clinical Practice (PFS2) - Full Analysis Set

To assess the efficacy of durvalumab and olaparib in terms of PFS2 in the first line treatment of patients with newly diagnosed advanced ovarian cancer. Time to second progression or death (PFS2) is defined as the time from the date of randomisation/allocation to the earliest of the progression event subsequent to first subsequent therapy or death. Results for tBRCAm SoC+D+O are not presented as this was prespecified to be assessed only in the Non-tBRCAm patients.

Time frame:
Assessed every 12 weeks after RECIST 1.1 defined progression. For global cohort, assessed until DCO3 (17MAR2025) - up to 73 months. For China cohort assessed until DCO1 (17MAR2025) - 46 months.
Reported as:
Median · Months
Time to Second Progression or Death Based on Local Standard Clinical Practice (PFS2) - Full Analysis Set
MonthsGlobal Non-tBRCAm: SoCGlobal Non-tBRCAm: SoC+DGlobal Non-tBRCAm: SoC+D+OChina Non-tBRCAm: SoCChina Non-tBRCAm: SoC+DChina Non-tBRCAm: SoC+D+O
Time to Second Progression or Death Based on Local Standard Clinical Practice (PFS2) - Full Analysis Set32.6 (30.7 to 35.4)34.6 (30.2 to 37.7)36.9 (32.7 to 41.1)27.5 (19.8 to NA)28.8 (22.6 to NA)NA (NA to NA)
Statistical analysis
  • Global Non-tBRCAm: SoC vs Global Non-tBRCAm: SoC+D+O · Hazard ratio (hr): 0.78 · 95% CI 0.65 to 0.93A HR less than 1 favours SoC+D+O
  • Global Non-tBRCAm: SoC vs Global Non-tBRCAm: SoC+D · Hazard ratio (hr): 0.89 · 95% CI 0.74 to 1.06A HR less than 1 favours SoC+D
  • China Non-tBRCAm: SoC vs China Non-tBRCAm: SoC+D+O · Hazard ratio (hr): 0.38 · 95% CI 0.14 to 0.90A HR less than 1 favours SoC+D+O
  • China Non-tBRCAm: SoC vs China Non-tBRCAm: SoC+D · Hazard ratio (hr): 0.97 · 95% CI 0.48 to 1.96A HR less than 1 favours SoC+D
PrimaryProgression-free Survival (PFS) by Investigator Assessment Using Modified RECIST 1.1 - Full Analysis Set

To determine the efficacy of durvalumab in combination with platinum based chemotherapy and bevacizumab and continued as maintenance in combination with bevacizumab and olaparib versus SoC platinum based chemotherapy in combination with bevacizumab by assessment of PFS (using investigator assessment according to Response Evaluation Criteria in Solid Tumours version 1.1 \[RECIST 1.1\]) in the first line treatment of patients with newly diagnosed advanced ovarian cancer. Per MTP, the comparison of SoC+D+O v SoC in the Non-tbRCAm patients is a primary endpoint. SoC+D v SoC is reported separately as a secondary endpoint. Results for tBRCAm SoC+D+O are not presented as this was prespecified to be assessed only in the Non-tBRCAm patients.

Time frame:
At baseline, within 3 weeks of last dose of chemotherapy, then every 12 weeks for 3 years and thereafter every 24 weeks. Assessed until primary analysis - (05DEC2022 for Global cohort, 17MAR2025 for China cohort) - upto 46 months
Reported as:
Median · Months
Progression-free Survival (PFS) by Investigator Assessment Using Modified RECIST 1.1 - Full Analysis Set
MonthsGlobal Non-tBRCAm: SoCGlobal Non-tBRCAm: SoC+D+OChina Non-tBRCAm: SoCChina Non-tBRCAm: SoC+D+O
Progression-free Survival (PFS) by Investigator Assessment Using Modified RECIST 1.1 - Full Analysis Set19.3 (17.9 to 20.3)24.2 (22.7 to 26.8)17.4 (11.7 to 26.4)26.8 (23.5 to NA)
Statistical analysis
  • Global Non-tBRCAm: SoC vs Global Non-tBRCAm: SoC+D+O · Log Rank · p = <0.0001 (The p-value is calculated using a log rank test stratified by timing and outcome of cytoreductive surgery' and 'geographic region'.) · Hazard ratio (hr): 0.63 · 95% CI 0.52 to 0.76A HR less than 1 favours SoC+D+O.
  • China Non-tBRCAm: SoC vs China Non-tBRCAm: SoC+D+O · Hazard ratio (hr): 0.47 · 95% CI 0.25 to 0.86A HR less than 1 favours SoC+D+O.
PrimaryProgression-free Survival (PFS) by Investigator Assessment Using Modified RECIST 1.1 - (Full Analysis Set, HRD Positive)

To determine the efficacy of durvalumab and olaparib assessed by PFS in the first line treatment of patients with newly diagnosed advanced ovarian cancer. Per MTP, the comparison of SoC+D+O v SoC in the Non-tBRCAm HRD positve population is a primary endpoint. SoC+D v SoC is reported separately as a secondary endpoint. Results for tBRCAm SoC+D+O are not presented as as this was prespecified to be assessed only in the Non-tBRCAm patients.

Time frame:
At baseline, within 3 weeks of last dose of chemotherapy, then every 12 weeks for 3 years and thereafter every 24 weeks. Assessed until DCO1 - (05DEC2022 for Global cohort, 17MAR2025 for China cohort) - upto 46 months
Reported as:
Median · Months
Progression-free Survival (PFS) by Investigator Assessment Using Modified RECIST 1.1 - (Full Analysis Set, HRD Positive)
MonthsGlobal Non-tBRCAm: SoCGlobal Non-tBRCAm: SoC+D+OChina Non-tBRCAm: SoCChina Non-tBRCAm: SoC+D+O
Progression-free Survival (PFS) by Investigator Assessment Using Modified RECIST 1.1 - (Full Analysis Set, HRD Positive)23 (21.2 to 24.8)37.3 (29.8 to NA)15.6 (9.3 to 23.9)26.8 (23.5 to NA)
Statistical analysis
  • Global Non-tBRCAm: SoC vs Global Non-tBRCAm: SoC+D+O · Log Rank · p = <0.0001 (The p-value is calculated using a log rank test stratified by timing and outcome of cytoreductive surgery'.) · Hazard ratio (hr): 0.49 · 95% CI 0.34 to 0.69A HR less than 1 favours SoC+D+O.
  • China Non-tBRCAm: SoC vs China Non-tBRCAm: SoC+D+O · Hazard ratio (hr): 0.39 · 95% CI 0.17 to 0.86A HR less than 1 favours SoC+D+O
SecondaryTime to Second Progression or Death Based on Local Standard Clinical Practice (PFS2) - (Full Analysis Set, HRD-positive)

To assess the efficacy of durvalumab and olaparib in terms of PFS2 in the first line treatment of patients with newly diagnosed advanced ovarian cancer. Time to second progression or death (PFS2) is defined as the time from the date of randomisation/allocation to the earliest of the progression event subsequent to first subsequent therapy or death. Results for tBRCAm SoC+D+O are not presented as this was prespecified to be assessed only in the Non-tBRCAm patients.

Time frame:
Assessed every 12 weeks after RECIST 1.1 defined progression. For global cohort, assessed until DCO3 (17MAR2025) - up to 73 months. For China cohort assessed until DCO1 (17MAR2025) - 46 months.
Reported as:
Median · Months
Time to Second Progression or Death Based on Local Standard Clinical Practice (PFS2) - (Full Analysis Set, HRD-positive)
MonthsGlobal Non-tBRCAm: SoCGlobal Non-tBRCAm: SoC+DGlobal Non-tBRCAm: SoC+D+OChina Non-tBRCAm: SoCChina Non-tBRCAm: SoC+DChina Non-tBRCAm: SoC+D+O
Time to Second Progression or Death Based on Local Standard Clinical Practice (PFS2) - (Full Analysis Set, HRD-positive)42.4 (38.8 to 58.9)51.3 (40.8 to NA)NA (NA to NA)NA (NA to NA)34.1 (22.2 to NA)NA (NA to NA)
Statistical analysis
  • Global Non-tBRCAm: SoC vs Global Non-tBRCAm: SoC+D+O · Hazard ratio (hr): 0.65 · 95% CI 0.46 to 0.92A HR less than 1 favours SoC+D+O
  • China Non-tBRCAm: SoC vs China Non-tBRCAm: SoC+D+O · Hazard ratio (hr): 0.37 · 95% CI 0.11 to 1.16A HR less than 1 favours SoC+D+O
SecondaryObjective Response Rate Based on Investigator Assessment (Full Analysis Set)

To assess the efficacy of durvalumab and olaparib in terms of ORR (Complete Response + Partial Response) by investigator assessment by modified RECIST 1.1: 1. in all patients with evaluable disease at baseline 2. prior to surgery in those patients planned to have IDS with evaluable disease at baseline. Objective response rate (ORR) is defined similarly for the non-tBRCAm and tBRCAm cohorts as the number (percentage) of patients with at least one investigator-assessed visit response of CR or PR and will be based on a subset of all randomised/allocated patients who have evaluable disease at baseline per the site investigator.

Time frame:
At baseline, within 3 weeks of last dose of chemotherapy, then every 12 weeks for 3 years and thereafter every 24 weeks. Up to 55 months for global non-tBRCAm (DCO2 18SEP2023). Up to 46 for Global tBRCAm (DCO1 05DEC2022) and China (DCO1 17MAR2025)
Reported as:
Number · Percentage of participants
Objective Response Rate Based on Investigator Assessment (Full Analysis Set)
Percentage of participantsGlobal Non-tBRCAm: SoCGlobal Non-tBRCAm: SoC+DGlobal Non-tBRCAm: SoC+D+OGlobal tBRCAm: SoC+D+OChina Non-tBRCAm: SoCChina Non-tBRCAm: SoC+DChina Non-tBRCAm: SoC+D+O
Objective Response Rate Based on Investigator Assessment (Full Analysis Set)70.368.174.372.657.756.766.7
SecondaryObjective Response Rate Based on Investigator Assessment (Full Analysis Set, HRD-positive)

To assess the efficacy of durvalumab and olaparib in terms of ORR (Complete Response + Partial Response) by investigator assessment by modified RECIST 1.1 1. in all patients with evaluable disease at baseline 2. prior to surgery in those patients planned to have IDS with evaluable disease at baseline. Objective response rate (ORR) is defined similarly for the non-tBRCAm and tBRCAm cohorts as the number (percentage) of patients with at least one investigator-assessed visit response of CR or PR and will be based on a subset of all randomised/allocated patients who have evaluable disease at baseline per the site investigator. This was prespecified to be assessed only in the non-tBRCAm cohort.

Time frame:
At baseline, within 3 weeks of last dose of chemotherapy, then every 12 weeks for 3 years and thereafter every 24 weeks. Up to 55 months for global non-tBRCAm (DCO2 18SEP2023). Up to 46 for China (DCO1 17MAR2025)
Reported as:
Number · Percentage of participants
Objective Response Rate Based on Investigator Assessment (Full Analysis Set, HRD-positive)
Percentage of participantsGlobal Non-tBRCAm: SoCGlobal Non-tBRCAm: SoC+DGlobal Non-tBRCAm: SoC+D+OChina Non-tBRCAm: SoCChina Non-tBRCAm: SoC+DChina Non-tBRCAm: SoC+D+O
Objective Response Rate Based on Investigator Assessment (Full Analysis Set, HRD-positive)82.473.885.456.371.466.7
SecondaryDuration of Objective Response Based on Investigator Assessments (Full Analysis Set)

To assess the efficacy of durvalumab and olaparib in terms of duration of response (DoR) in the first line treatment of patients with newly diagnosed advanced ovarian cancer. Duration of response (DoR) is defined similarly for the non-tBRCAm and tBRCAm cohorts using the corresponding FAS among patients with a response (CR or PR), as the time from the date of first documented response (i.e., the first time at which the visit response is PR or CR) according to modified RECIST v1.1 as assessed by the investigator until date of documented progression or death in the absence of disease progression. This was prespecified to be assessed only in the Global patients.

Time frame:
At baseline, within 3 weeks of last dose of chemotherapy, then every 12 weeks for 3 years and thereafter every 24 weeks. Up to 55 months for global non-tBRCAm (DCO2 18SEP2023). Up to 46 for Global tBRCAm (DCO1 05DEC2022)
Reported as:
Median · Months
Duration of Objective Response Based on Investigator Assessments (Full Analysis Set)
MonthsGlobal Non-tBRCAm - SoCGlobal Non-tBRCAm - SoC+DGlobal Non-tBRCAm - SoC+D+OGlobal tBRCAm - SoC+D+O
Duration of Objective Response Based on Investigator Assessments (Full Analysis Set)16.4 (8.3 to 23.8)15.9 (8.4 to 28.3)22.3 (12.1 to NA)NA (24.9 to NA)
SecondaryDuration of Objective Response Based on Investigator Assessments (Full Analysis Set, HRD-positive)

To assess the efficacy of durvalumab and olaparib in terms of duration of response (DoR) in the first line treatment of patients with newly diagnosed advanced ovarian cancer. Duration of response (DoR) is defined similarly for the non-tBRCAm and tBRCAm cohorts using the corresponding FAS among patients with a response (CR or PR), as the time from the date of first documented response (i.e., the first time at which the visit response is PR or CR) according to modified RECIST v1.1 as assessed by the investigator until date of documented progression or death in the absence of disease progression. This was prespecified to be assessed only in Global Non-tBRCAm patients.

Time frame:
At baseline, within 3 weeks of last dose of chemotherapy, then every 12 weeks for 3 years and thereafter every 24 weeks. Up to 55 months for global non-tBRCAm (DCO2 18SEP2023).
Reported as:
Median · Months
Duration of Objective Response Based on Investigator Assessments (Full Analysis Set, HRD-positive)
MonthsGlobal Non-tBRCAm - SoCGlobal Non-tBRCAm - SoC+DGlobal Non-tBRCAm - SoC+D+O
Duration of Objective Response Based on Investigator Assessments (Full Analysis Set, HRD-positive)19.4 (12.5 to 47.8)19.3 (11.5 to 34.5)31.3 (18.4 to NA)
SecondaryTime to First Subsequent Therapy (TFST) - Full Analysis Set

To assess the efficacy of durvalumab and olaparib in terms of TFST in the first line treatment of patients with newly diagnosed advanced ovarian cancer. Time to start of first subsequent therapy or death (TFST) is defined as the time from randomisation/allocation to the earlier of first subsequent therapy start date following study treatment discontinuation, or death. This was prespecified to be assessed only in Non-tBRCAm patients.

Time frame:
Assessed every 12 weeks following treatment discontinuation. For global cohort, assessed until DCO3 (17MAR2025) - up to 73 months. For China cohort assessed until DCO1 (17MAR2025) - up to 46 months.
Reported as:
Median · Months
Time to First Subsequent Therapy (TFST) - Full Analysis Set
MonthsGlobal Non-tBRCAm: SoCGlobal Non-tBRCAm: SoC+DGlobal Non-tBRCAm: SoC+D+OChina Non-tBRCAm: SoCChina Non-tBRCAm: SoC+DChina Non-tBRCAm: SoC+D+O
Time to First Subsequent Therapy (TFST) - Full Analysis Set21.6 (20.1 to 23.4)21.9 (19.8 to 23.4)26.3 (24.2 to 29.5)19.0 (12.4 to 27.6)21.7 (15.6 to NA)NA (NA to NA)
Statistical analysis
  • Global Non-tBRCAm: SoC vs Global Non-tBRCAm: SoC+D+O · Hazard ratio (hr): 0.68 · 95% CI 0.58 to 0.80A HR less than 1 favours SoC+D+O
  • Global Non-tBRCAm: SoC vs Global Non-tBRCAm: SoC+D · Hazard ratio (hr): 0.87 · 95% CI 0.74 to 1.03A HR less than 1 favours SoC+D
  • China Non-tBRCAm: SoC vs China Non-tBRCAm: SoC+D+O · Hazard ratio (hr): 0.47 · 95% CI 0.25 to 0.86A HR less than 1 favours SoC+D+O
  • China Non-tBRCAm: SoC vs China Non-tBRCAm: SoC+D · Hazard ratio (hr): 0.87 · 95% CI 0.50 to 1.52A HR less than 1 favours SoC+D
SecondaryTime to First Subsequent Therapy (TFST) - (Full Analysis Set, HRD-positive)

To assess the efficacy of durvalumab and olaparib in terms of TFST in the first line treatment of patients with newly diagnosed advanced ovarian cancer. Time to start of first subsequent therapy or death (TFST) is defined as the time from randomisation/allocation to the earlier of first subsequent therapy start date following study treatment discontinuation, or death. This was prespecified to be assessed only in Non-tBRCAm patients.

Time frame:
Assessed every 12 weeks following treatment discontinuation. For global cohort, assessed until DCO3 (17MAR2025) - up to 73 months. For China cohort assessed until DCO1 (17MAR2025) - up to 46 months.
Reported as:
Median · Months
Time to First Subsequent Therapy (TFST) - (Full Analysis Set, HRD-positive)
MonthsGlobal Non-tBRCAm: SoCGlobal Non-tBRCAm: SoC+DGlobal Non-tBRCAm: SoC+D+OChina Non-tBRCAm: SoCChina Non-tBRCAm: SoC+DChina Non-tBRCAm: SoC+D+O
Time to First Subsequent Therapy (TFST) - (Full Analysis Set, HRD-positive)25.8 (23.5 to 30.9)29.0 (25.1 to 39.2)41.4 (33.2 to 59.2)17.9 (11.7 to NA)34.1 (16.8 to NA)NA (NA to NA)
Statistical analysis
  • Global Non-tBRCAm: SoC vs Global Non-tBRCAm: SoC+D+O · Hazard ratio (hr): 0.57 · 95% CI 0.42 to 0.77A HR less than 1 favours SoC+D+O
  • China Non-tBRCAm: SoC vs China Non-tBRCAm: SoC+D+O · Hazard ratio (hr): 0.48 · 95% CI 0.21 to 1.06A HR less than 1 favours SoC+D+O
SecondaryTime to Second Subsequent Therapy (TSST) - Full Analysis Set

To assess the efficacy of durvalumab and olaparib in terms of TSST in the first line treatment of patients with newly diagnosed advanced ovarian cancer. Time to second subsequent therapy or death (TSST) is defined as the time from randomisation/allocation to the earlier of the second subsequent anti-cancer therapy start date following study treatment discontinuation, or death. This was prespecified to be assessed only in Non-tBRCAm patients.

Time frame:
Assessed every 12 weeks following treatment discontinuation. For global cohort, assessed until DCO3 (17MAR2025) - up to 73 months. For China cohort assessed until DCO1 (17MAR2025) - up to 46 months.
Reported as:
Median · Months
Time to Second Subsequent Therapy (TSST) - Full Analysis Set
MonthsGlobal Non-tBRCAm: SoCGlobal Non-tBRCAm: SoC+DGlobal Non-tBRCAm: SoC+D+OChina Non-tBRCAm: SoCChina Non-tBRCAm: SoC+DChina Non-tBRCAm: SoC+D+O
Time to Second Subsequent Therapy (TSST) - Full Analysis Set33.1 (31.6 to 36.6)34.9 (31.8 to 37.8)38.5 (34.6 to 42.1)NA (NA to NA)30.6 (22.2 to NA)NA (NA to NA)
Statistical analysis
  • Global Non-tBRCAm: SoC vs Global Non-tBRCAm: SoC+D+O · Hazard ratio (hr): 0.79 · 95% CI 0.65 to 0.94A HR less than 1 favours SoC+D+O
  • Global Non-tBRCAm: SoC vs Global Non-tBRCAm: SoC+D · Hazard ratio (hr): 0.93 · 95% CI 0.78 to 1.12A HR less than 1 favours SoC+D
  • China Non-tBRCAm: SoC vs China Non-tBRCAm: SoC+D+O · Hazard ratio (hr): 0.36 · 95% CI 0.14 to 0.85A HR less than 1 favours SoC+D+O
  • China Non-tBRCAm: SoC vs China Non-tBRCAm: SoC+D · Hazard ratio (hr): 0.98 · 95% CI 0.49 to 1.99A HR less than 1 favours SoC+D
SecondaryTime to Second Subsequent Therapy (TSST) - (Full Analysis Set, HRD-positive)

To assess the efficacy of durvalumab and olaparib in terms of TSST in the first line treatment of patients with newly diagnosed advanced ovarian cancer. Time to second subsequent therapy or death (TSST) is defined as the time from randomisation to the earlier of the second subsequent anti-cancer therapy start date following study treatment discontinuation, or death. This was prespecified to be assessed only in Non-tBRCAm patients.

Time frame:
Assessed every 12 weeks following treatment discontinuation. For global cohort, assessed until DCO3 (17MAR2025) - up to 73 months. For China cohort assessed until DCO1 (17MAR2025) - up to 46 months.
Reported as:
Median · Months
Time to Second Subsequent Therapy (TSST) - (Full Analysis Set, HRD-positive)
MonthsGlobal Non-tBRCAm: SoCGlobal Non-tBRCAm: SoC+DGlobal Non-tBRCAm: SoC+D+OChina Non-tBRCAm: SoCChina Non-tBRCAm: SoC+DChina Non-tBRCAm: SoC+D+O
Time to Second Subsequent Therapy (TSST) - (Full Analysis Set, HRD-positive)46.8 (39.5 to 60.0)48.4 (41.8 to NA)NA (NA to NA)NA (NA to NA)34.1 (22.2 to NA)NA (NA to NA)
Statistical analysis
  • Global Non-tBRCAm: SoC vs Global Non-tBRCAm: SoC+D+O · Hazard ratio (hr): 0.67 · 95% CI 0.47 to 0.96A HR less than 1 favours SoC+D+O
  • China Non-tBRCAm: SoC vs China Non-tBRCAm: SoC+D+O · Hazard ratio (hr): 0.36 · 95% CI 0.11 to 1.14A HR less than 1 favours SoC+D+O
SecondaryTime to Treatment Discontinuation (TDT) - Full Analysis Set

To assess the efficacy of durvalumab and olaparib in terms of TDT in the first line treatment of patients with newly diagnosed advanced ovarian cancer. Time to permanent study treatment discontinuation or death (TDT) is defined as the time from randomisation/allocation to the earlier of the date of permanent study treatment discontinuation or death. This was prespecified to be assessed only in Non-tBRCAm patients.

Time frame:
Assessed through study completion, up to 73 months for global non-tBRCAm (DCO3 17MAR2025) and up to 46 months for and China (DCO1 17MAR2025)
Reported as:
Median · Months
Time to Treatment Discontinuation (TDT) - Full Analysis Set
MonthsGlobal Non-tBRCAm: SoCGlobal Non-tBRCAm: SoC+DGlobal Non-tBRCAm: SoC+D+OChina Non-tBRCAm: SoCChina Non-tBRCAm: SoC+DChina Non-tBRCAm: SoC+D+O
Time to Treatment Discontinuation (TDT) - Full Analysis Set18.4 (17.1 to 19.7)17.5 (15.2 to 19.4)20.4 (18.5 to 21.7)14.8 (10.4 to 23.0)14.5 (9.0 to 22.4)22.0 (15.4 to 26.1)
Statistical analysis
  • Global Non-tBRCAm: SoC vs Global Non-tBRCAm: SoC+D+O · Hazard ratio (hr): 0.88 · 95% CI 0.76 to 1.02A HR less than 1 favours SoC+D+O
  • Global Non-tBRCAm: SoC vs Global Non-tBRCAm: SoC+D · Hazard ratio (hr): 0.98 · 95% CI 0.85 to 1.13A HR less than 1 favours SoC+D
  • China Non-tBRCAm: SoC vs China Non-tBRCAm: SoC+D+O · Hazard ratio (hr): 0.82 · 95% CI 0.50 to 1.34A HR less than 1 favours SoC+D+O
  • China Non-tBRCAm: SoC vs China Non-tBRCAm: SoC+D · Hazard ratio (hr): 0.86 · 95% CI 0.52 to 1.43A HR less than 1 favours SoC+D
SecondaryTime to Treatment Discontinuation (TDT) - (Full Analysis Set, HRD-positive)

To assess the efficacy of durvalumab and olaparib in terms of TDT in the first line treatment of patients with newly diagnosed advanced ovarian cancer. Time to permanent study treatment discontinuation or death (TDT) is defined as the time from randomisation/allocation to the earlier of the date of permanent study treatment discontinuation or death. This was prespecified to be assessed only in Non-tBRCAm patients.

Time frame:
Assessed through study completion, up to 73 months for global non-tBRCAm (DCO3 17MAR2025) and up to 46 months for and China (DCO1 17MAR2025)
Reported as:
Median · Months
Time to Treatment Discontinuation (TDT) - (Full Analysis Set, HRD-positive)
MonthsGlobal Non-tBRCAm: SoCGlobal Non-tBRCAm: SoC+DGlobal Non-tBRCAm: SoC+D+OChina Non-tBRCAm: SoCChina Non-tBRCAm: SoC+DChina Non-tBRCAm: SoC+D+O
Time to Treatment Discontinuation (TDT) - (Full Analysis Set, HRD-positive)22.0 (20.5 to 24.9)22.3 (19.4 to 24.3)24.7 (21.9 to 27.5)15.7 (9.2 to 24.0)20.0 (11.8 to NA)21.8 (14.6 to 26.1)
Statistical analysis
  • Global Non-tBRCAm: SoC vs Global Non-tBRCAm: SoC+D+O · Hazard ratio (hr): 0.84 · 95% CI 0.66 to 1.06A HR less than 1 favours SoC+D+O
  • China Non-tBRCAm: SoC vs China Non-tBRCAm: SoC+D+O · Hazard ratio (hr): 0.77 · 95% CI 0.40 to 1.49A HR less than 1 favours SoC+D+O
SecondaryChange From Baseline in Physical Function Score of the EORTC-QLQ-C30 and EORTC-QLQ-OV28 Questionnaires - Full Analysis Set

To determine the effects on HRQoL, global health status and ovarian cancer symptoms of the combination of durvalumab and olaparib in the first line treatment of non-tBRCAm patients with newly diagnosed advanced ovarian cancer. The physical functioning score is a score from 0 to 100. Higher scores on the physical functioning score indicate better health status/function. This was prespecified to be assessed only in Global Non-tBRCAm patients.

Time frame:
Assessed at week 96.
Reported as:
Least squares mean · Score on a scale
Change From Baseline in Physical Function Score of the EORTC-QLQ-C30 and EORTC-QLQ-OV28 Questionnaires - Full Analysis Set
Score on a scaleGlobal Non-tBRCAm: SoCGlobal Non-tBRCAm: SoC+DGlobal Non-tBRCAm: SoC+D+O
Change From Baseline in Physical Function Score of the EORTC-QLQ-C30 and EORTC-QLQ-OV28 Questionnaires - Full Analysis Set6.3 ± 1.303.3 ± 1.253.0 ± 1.31
Statistical analysis
  • Global Non-tBRCAm: SoC vs Global Non-tBRCAm: SoC+D+O · Ls mean difference: -3.2 · 95% CI -6.73 to 0.27Analyses of QLQ-C30/QLQ-OV28 scores were performed using linear random coefficient mixed models with nodes set at scheduled assessment days.
  • Global Non-tBRCAm: SoC+D vs Global Non-tBRCAm: SoC+D+O · Ls mean difference: -3.0 · 95% CI -6.42 to 0.44Analyses of QLQ-C30/QLQ-OV28 scores were performed using linear random coefficient mixed models with nodes set at scheduled assessment days.
SecondaryChange From Baseline in Physical Function Score of the EORTC-QLQ-C30 and EORTC-QLQ-OV28 Questionnaires - (Full Analysis Set, HRD Positive)

To determine the effects on HRQoL, global health status and ovarian cancer symptoms of the combination of durvalumab and olaparib in the first line treatment of non-tBRCAm patients with newly diagnosed advanced ovarian cancer. The physical functioning score is a score from 0 to 100. Higher scores on the physical functioning score indicate better health status/function. This was prespecified to be assessed only in Global Non-tBRCAm patients.

Time frame:
Assessed at week 96.
Reported as:
Least squares mean · Score on a scale
Change From Baseline in Physical Function Score of the EORTC-QLQ-C30 and EORTC-QLQ-OV28 Questionnaires - (Full Analysis Set, HRD Positive)
Score on a scaleGlobal Non-tBRCAm: SoCGlobal Non-tBRCAm: SoC+DGlobal Non-tBRCAm: SoC+D+O
Change From Baseline in Physical Function Score of the EORTC-QLQ-C30 and EORTC-QLQ-OV28 Questionnaires - (Full Analysis Set, HRD Positive)9.8 ± 1.534.9 ± 1.887.6 ± 1.61
Statistical analysis
  • Global Non-tBRCAm: SoC vs Global Non-tBRCAm: SoC+D+O · Ls mean difference: -2.2 · 95% CI -6.42 to 1.92Analyses of QLQ-C30/QLQ-OV28 scores were performed using linear random coefficient mixed models with nodes set at scheduled assessment days.
  • Global Non-tBRCAm: SoC+D vs Global Non-tBRCAm: SoC+D+O · Ls mean difference: -4.9 · 95% CI -9.51 to -0.27Analyses of QLQ-C30/QLQ-OV28 scores were performed using linear random coefficient mixed models with nodes set at scheduled assessment days.
SecondaryChange From Baseline in Global Health Status/QoL Score of the EORTC-QLQ-C30 and EORTC-QLQ-OV28 Questionnaires - Full Analysis Set

To determine the effects on HRQoL, global health status and ovarian cancer symptoms of the combination of durvalumab and olaparib in the first line treatment of non-tBRCAm patients with newly diagnosed advanced ovarian cancer. The global health status/quality of life (QoL) is a score from 0 to 100. Higher scores on the global health status/QoL indicate better health status/function. This was prespecified to be assessed only in Global Non-tBRCAm patients.

Time frame:
Assessed at week 96.
Reported as:
Least squares mean · Score on a scale
Change From Baseline in Global Health Status/QoL Score of the EORTC-QLQ-C30 and EORTC-QLQ-OV28 Questionnaires - Full Analysis Set
Score on a scaleGlobal Non-tBRCAm: SoCGlobal Non-tBRCAm: SoC+DGlobal Non-tBRCAm: SoC+D+O
Change From Baseline in Global Health Status/QoL Score of the EORTC-QLQ-C30 and EORTC-QLQ-OV28 Questionnaires - Full Analysis Set6.3 ± 1.233.8 ± 1.334.6 ± 1.19
Statistical analysis
  • Global Non-tBRCAm: SoC vs Global Non-tBRCAm: SoC+D+O · Ls mean difference: -1.7 · 95% CI -4.96 to 1.47Analyses of QLQ-C30/QLQ-OV28 scores were performed using linear random coefficient mixed models with nodes set at scheduled assessment days.
  • Global Non-tBRCAm: SoC+D vs Global Non-tBRCAm: SoC+D+O · Ls mean difference: -2.5 · 95% CI -5.89 to 0.90Analyses of QLQ-C30/QLQ-OV28 scores were performed using linear random coefficient mixed models with nodes set at scheduled assessment days.
SecondaryChange From Baseline in Global Health Status/QoL Score of the EORTC-QLQ-C30 and EORTC-QLQ-OV28 Questionnaires - (Full Analysis Set, HRD Positive)

To determine the effects on HRQoL, global health status and ovarian cancer symptoms of the combination of durvalumab and olaparib in the first line treatment of non-tBRCAm patients with newly diagnosed advanced ovarian cancer. The global health status/quality of life (QoL) is a score from 0 to 100. Higher scores on the global health status/QoL indicate better health status/function. This was prespecified to be assessed only in Global Non-tBRCAm patients.

Time frame:
Assessed at week 96
Reported as:
Least squares mean · Score on a scale
Change From Baseline in Global Health Status/QoL Score of the EORTC-QLQ-C30 and EORTC-QLQ-OV28 Questionnaires - (Full Analysis Set, HRD Positive)
Score on a scaleGlobal Non-tBRCAm: SoCGlobal Non-tBRCAm: SoC+DGlobal Non-tBRCAm: SoC+D+O
Change From Baseline in Global Health Status/QoL Score of the EORTC-QLQ-C30 and EORTC-QLQ-OV28 Questionnaires - (Full Analysis Set, HRD Positive)8.5 ± 1.756.3 ± 1.977.0 ± 1.64
Statistical analysis
  • Global Non-tBRCAm: SoC vs Global Non-tBRCAm: SoC+D+O · Ls mean difference: -1.5 · 95% CI -6.02 to 2.96Analyses of QLQ-C30/QLQ-OV28 scores were performed using linear random coefficient mixed models with nodes set at scheduled assessment days.
  • Global Non-tBRCAm: SoC+D vs Global Non-tBRCAm: SoC+D+O · Ls mean difference: -2.3 · 95% CI -7.27 to 2.75Analyses of QLQ-C30/QLQ-OV28 scores were performed using linear random coefficient mixed models with nodes set at scheduled assessment days.
SecondarySummary of Serum Concentrations (μg/mL) of Durvalumab for Each Treatment - Non-tBRCAm Cohort With Primary Cytoreductive Surgery (Pharmacokinetic Analysis Set)

To characterize the PK of durvalumab in combination with bevacizumab and olaparib. This was prespecified to be assessed only in Global Non-tBRCAm patients.

Time frame:
Assessed at Day 85 pre-dose, Day 183 pre-dose and 3 months after last dose of durvalumab.
Reported as:
Geometric mean · μg/mL
Summary of Serum Concentrations (μg/mL) of Durvalumab for Each Treatment - Non-tBRCAm Cohort With Primary Cytoreductive Surgery (Pharmacokinetic Analysis Set)
μg/mLGlobal Non-tBRCAm: SoC+DGlobal Non-tBRCAm: SoC+D+O
Day 85, pre-dose218376.482 ± 40.8207988.974 ± 30.1
Day 148, pre-dose237360.027 ± 36.8252257.020 ± 39.9
Follow-up (3 months after last dose of durvalumab.)38355.597 ± 112.325776.441 ± 218.4
SecondarySummary of Plasma Concentrations (μg/mL) of Olaparib - Non-tBRCAm Cohort With Primary Cytoreductive Surgery (Pharmacokinetic Analysis Set)

To determine olaparib plasma concentrations via sparse sampling for population PK analyses. This was prespecified to be assessed only in Global Non-tBRCAm patients.

Time frame:
Assessed on Day 148 post-dose (1-3 hours, 3-6 hours and 6-12 hours)
Reported as:
Geometric mean · μg/mL
Summary of Plasma Concentrations (μg/mL) of Olaparib - Non-tBRCAm Cohort With Primary Cytoreductive Surgery (Pharmacokinetic Analysis Set)
μg/mLGlobal Non-tBRCAm: SoC+D+O
Day 148, 1-3 hours5.8563 ± 47.7
Day 148, 3-6 hours4.2425 ± 38.4
Day 148, 6-12 hours2.5059 ± 44.2
SecondarySummary of ADA Responses During the Study for Durvalumab - Non-tBRCAm Cohort With Primary Cytoreductive Surgery (ADA Analysis Set)

To characterize the immunogenicity of durvalumab in combination with bevacizumab and olaparib. This was prespecified to be assessed only in Global Non-tBRCAm patients.

Time frame:
Assessed pre-infusion at Cycle 2, Cycle 4, Cycle 6 and the third cycle of the maintenance phase as well as 3 months after last dose of durvalumab
Reported as:
Number · Number of participants
Summary of ADA Responses During the Study for Durvalumab - Non-tBRCAm Cohort With Primary Cytoreductive Surgery (ADA Analysis Set)
Number of participantsGlobal Non-tBRCAm: SoCGlobal Non-tBRCAm: SoC+DGlobal Non-tBRCAm: SoC+D+O
ADA positive at any visit (ADA Prevalence)426
Treatment-emergent ADA-positive (ADA incidence)101
Treatment-boosted ADA000
Treatment-induced ADA (Positive Post-baseline only)101
ADA positive at baseline only325
ADA Positive Post-baseline and Positive at Baseline000
Persistently positive000
Transiently positive101
Neutralising antibody positive at any visit000

Adverse events

Collected over For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Global Non-tBRCAm: SoC205/378 (54.2%)132/376 (35.1%)369/376 (98.1%)
Global Non-tBRCAm: SoC + Durvalumab200/374 (53.5%)165/373 (44.2%)367/373 (98.4%)
Global Non-tBRCAm: SoC + Durvalumab + Olaparib193/378 (51.1%)152/378 (40.2%)372/378 (98.4%)
Global tBRCAm: SoC + Durvalumab + Olaparib47/154 (30.5%)74/153 (48.4%)151/153 (98.7%)
China Non-tBRCAm: SoC14/40 (35%)19/40 (47.5%)40/40 (100%)
China Non-tBRCAm: SoC + Durvalumab11/43 (25.6%)17/43 (39.5%)43/43 (100%)
China Non-tBRCAm: SoC + Durvalumab + Olaparib7/41 (17.1%)22/41 (53.7%)41/41 (100%)
Most frequent serious events
Showing 10 of 364
Most frequent serious events
EventGlobal Non-tBRCAm: SoCGlobal Non-tBRCAm: SoC + DurvalumabGlobal Non-tBRCAm: SoC + Durvalumab + OlaparibGlobal tBRCAm: SoC + Durvalumab + OlaparibChina Non-tBRCAm: SoCChina Non-tBRCAm: SoC + DurvalumabChina Non-tBRCAm: SoC + Durvalumab + Olaparib
AnaemiaBlood and lymphatic system disorders5/3763/37312/3781/1531/401/435/41
Covid-19Infections and infestations4/3767/3738/3781/1530/400/433/41
Intestinal obstructionGastrointestinal disorders4/3764/3732/3782/1532/402/433/41
PneumoniaInfections and infestations1/3761/3735/3783/1531/403/430/41
Febrile neutropeniaBlood and lymphatic system disorders9/37610/37312/3789/1530/401/430/41
Hepatic function abnormalHepatobiliary disorders0/3760/3731/3780/1532/400/431/41
Platelet count decreasedInvestigations0/3760/3730/3780/1532/402/431/41
ProteinuriaRenal and urinary disorders0/3760/3730/3780/1532/400/431/41
Pleural effusionRespiratory, thoracic and mediastinal disorders1/3762/3731/3780/1532/400/430/41
Upper respiratory tract infectionInfections and infestations1/3761/3730/3780/1530/401/432/41
Most frequent other events
Showing 10 of 109
Most frequent other events
EventGlobal Non-tBRCAm: SoCGlobal Non-tBRCAm: SoC + DurvalumabGlobal Non-tBRCAm: SoC + Durvalumab + OlaparibGlobal tBRCAm: SoC + Durvalumab + OlaparibChina Non-tBRCAm: SoCChina Non-tBRCAm: SoC + DurvalumabChina Non-tBRCAm: SoC + Durvalumab + Olaparib
AnaemiaBlood and lymphatic system disorders103/376119/373203/37884/15330/4032/4334/41
Neutrophil count decreasedInvestigations59/37656/37367/37824/15327/4023/4328/41
White blood cell count decreasedInvestigations38/37639/37353/37816/15324/4025/4327/41
NauseaGastrointestinal disorders115/376111/373219/37879/15315/4022/4325/41
Platelet count decreasedInvestigations31/37638/37351/37819/15319/4021/4325/41
Aspartate aminotransferase increasedInvestigations13/37628/37327/3788/15319/4018/4320/41
HypoaesthesiaNervous system disorders1/3765/3736/3783/15312/4012/4320/41
Alanine aminotransferase increasedInvestigations23/37626/37331/3788/15312/4016/4319/41
VomitingGastrointestinal disorders60/37662/37397/37841/1539/4013/4318/41
Weight increasedInvestigations8/3769/3739/3788/15316/4018/438/41

Baseline characteristics

1 patient in the China cohort is also included in the Global cohort. Patient is randomised to SoC+Durvalumab.

Age, Continuous
Age, Continuous(Years)Global Non-tBRCAm: SoCGlobal Non-tBRCAm: SoC + DurvalumabGlobal Non-tBRCAm: SoC + Durvalumab + OlaparibGlobal tBRCAm: SoC + Durvalumab + OlaparibChina Non-tBRCAm: SoCChina Non-tBRCAm: SoC + DurvalumabChina Non-tBRCAm: SoC + Durvalumab + OlaparibTotal
Mean58.7 ± 9.958.5 ± 10.860.2 ± 10.455.7 ± 10.358.8 ± 8.652.8 ± 8.753.9 ± 9.458.4 ± 10.4
Age, Customized
Age, Customized(Participants)Global Non-tBRCAm: SoCGlobal Non-tBRCAm: SoC + DurvalumabGlobal Non-tBRCAm: SoC + Durvalumab + OlaparibGlobal tBRCAm: SoC + Durvalumab + OlaparibChina Non-tBRCAm: SoCChina Non-tBRCAm: SoC + DurvalumabChina Non-tBRCAm: SoC + Durvalumab + OlaparibTotal
>=65110126135371045427
<65268248243117303936981
Sex/Gender, Customized
Sex/Gender, Customized(Participants)Global Non-tBRCAm: SoCGlobal Non-tBRCAm: SoC + DurvalumabGlobal Non-tBRCAm: SoC + Durvalumab + OlaparibGlobal tBRCAm: SoC + Durvalumab + OlaparibChina Non-tBRCAm: SoCChina Non-tBRCAm: SoC + DurvalumabChina Non-tBRCAm: SoC + Durvalumab + OlaparibTotal
Female3783743781544043411408
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Global Non-tBRCAm: SoCGlobal Non-tBRCAm: SoC + DurvalumabGlobal Non-tBRCAm: SoC + Durvalumab + OlaparibGlobal tBRCAm: SoC + Durvalumab + OlaparibChina Non-tBRCAm: SoCChina Non-tBRCAm: SoC + DurvalumabChina Non-tBRCAm: SoC + Durvalumab + OlaparibTotal
Hispanic or Latino292025500079
Not Hispanic or Latino3453473461494043411311
Unknown or Not Reported477000018
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Global Non-tBRCAm: SoCGlobal Non-tBRCAm: SoC + DurvalumabGlobal Non-tBRCAm: SoC + Durvalumab + OlaparibGlobal tBRCAm: SoC + Durvalumab + OlaparibChina Non-tBRCAm: SoCChina Non-tBRCAm: SoC + DurvalumabChina Non-tBRCAm: SoC + Durvalumab + OlaparibTotal
AMERICAN INDIAN OR ALASKA NATIVE441100010
ASIAN55524745404341323
BLACK OR AFRICAN AMERICAN334100011
MISSING16100008
NATIVE HAWAIIAN OR OTHER PACIFIC ISLANDER00000000
OTHER231619100059
WHITE292293306106000997
08

Study locations

214 sites
  • Research Site
    Foothill Ranch, California 92610, United States
  • Research Site
    Los Angeles, California 90095, United States
  • Research Site
    Orange, California 92868-3298, United States
  • Research Site
    San Francisco, California 94158, United States
  • Research Site
    Tampa, Florida 33612, United States
  • Research Site
    Augusta, Georgia 30912, United States
  • Research Site
    Hinsdale, Illinois 60521, United States
  • Research Site
    Indianapolis, Indiana 46202, United States
  • Research Site
    Towson, Maryland 21204, United States
  • Research Site
    Detroit, Michigan 48202, United States
  • Research Site
    Springfield, Missouri 65807, United States
  • Research Site
    Middletown, New Jersey 07748, United States
  • Research Site
    Montvale, New Jersey 07645, United States
  • Research Site
    Albany, New York 12208, United States
  • Research Site
    New York, New York 10065, United States
  • Research Site
    Uniondale, New York 11553, United States
  • Research Site
    Durham, North Carolina 27710, United States
  • Research Site
    Cleveland, Ohio 44195, United States
  • Research Site
    Dayton, Ohio 45429, United States
  • Research Site
    Hilliard, Ohio 43026, United States
  • Research Site
    Tulsa, Oklahoma 74134, United States
  • Research Site
    Lancaster, Pennsylvania 17601, United States
  • Research Site
    Philadelphia, Pennsylvania 19104, United States
  • Research Site
    Philadelphia, Pennsylvania 19107-5097, United States
  • Research Site
    Pittsburgh, Pennsylvania 15224, United States
  • Research Site
    Salt Lake City, Utah 84112, United States
  • Research Site
    Graz, 8036, Austria
  • Research Site
    Innsbruck, 6020, Austria
  • Research Site
    Linz, 4020, Austria
  • Research Site
    Vienna, 1090, Austria
  • Research Site
    Aalst, 9300, Belgium
  • Research Site
    Leuven, 3000, Belgium
  • Research Site
    Namur, 5000, Belgium
  • Research Site
    Ostend, 8400, Belgium
  • Research Site
    Sint-Niklaas, 9100, Belgium
  • Research Site
    Barretos, 14784-400, Brazil
  • Research Site
    Florianópolis, 88034-000, Brazil
  • Research Site
    Fortaleza, 60810-180, Brazil
  • Research Site
    Londrina, 86015-520, Brazil
  • Research Site
    Porto Alegre, 90020-090, Brazil
  • Research Site
    Porto Alegre, 90110-270, Brazil
  • Research Site
    Rio de Janeiro, 20220-410, Brazil
  • Research Site
    São Paulo, 01317-000, Brazil
  • Research Site
    São Paulo, 04014-002, Brazil
  • Research Site
    Burgas, 8000, Bulgaria
  • Research Site
    Plovdiv, 4004, Bulgaria
  • Research Site
    Sofia, 1330, Bulgaria
  • Research Site
    Varna, 9000, Bulgaria
  • Research Site
    Calgary, Alberta T2N 5G2, Canada
  • Research Site
    Barrie, Ontario L4M 6M2, Canada
  • Research Site
    Greater Sudbury, Ontario P3E 5J1, Canada
  • Research Site
    Toronto, Ontario M5G 2M9, Canada
  • Research Site
    Montreal, Quebec H2X 3E4, Canada
  • Research Site
    Montreal, Quebec H3T 1E2, Canada
  • Research Site
    Montreal, Quebec H4A 3J1, Canada
  • Research Site
    Québec, Quebec G1J 1Z4, Canada
  • Research Site
    Rimouski, Quebec G5L 5T1, Canada
  • Research Site
    Beijing, 100026, China
  • Research Site
    Beijing, CN-100730, China
  • Research Site
    Bengbu, 233004, China
  • Research Site
    Changchun, 130021, China
  • Research Site
    Changsha, 410008, China
  • Research Site
    Changsha, 430033, China
  • Research Site
    Chengdu, 610041, China
  • Research Site
    Chongqing, 400030, China
  • Research Site
    Dalian, 116001, China
  • Research Site
    Guangzhou, 510060, China
  • Research Site
    Guangzhou, 510080, China
  • Research Site
    Hangzhou, 310009, China
  • Research Site
    Hangzhou, 310022, China
  • Research Site
    Harbin, 150081, China
  • Research Site
    Hefei, 230031, China
  • Research Site
    Jinhua, 321099, China
  • Research Site
    Kunming, 650118, China
  • Research Site
    Lanzhou, 730030, China
  • Research Site
    Luzhou, 646099, China
  • Research Site
    Nanchong, 637000, China
  • Research Site
    Nanjing, 2100008, China
  • Research Site
    Nanning, 530021, China
  • Research Site
    Nantong, 226361, China
  • Research Site
    Shanghai, 200011, China
  • Research Site
    Shanghai, 200032, China
  • Research Site
    Wuhan, 430030, China
  • Research Site
    Wuhan, 430060, China
  • Research Site
    Xi'an, 710061, China
  • Research Site
    Zhengzhou, 450002, China
  • Research Site
    Zhengzhou, 450008, China
  • Research Site
    Zhuhai, 519099, China
  • Research Site
    Aalborg, 9000, Denmark
  • Research Site
    Aarhus N, 8200, Denmark
  • Research Site
    Odense, 5000, Denmark
  • Research Site
    Roskilde, 4000, Denmark
  • Research Site
    Vejle, 7100, Denmark
  • Research Site
    Kuopio, 70210, Finland
  • Research Site
    Oulu, 90029, Finland
  • Research Site
    Turku, 20521, Finland
  • Research Site
    Besançon, 25000, France
  • Research Site
    Bordeaux, 33076, France
  • Research Site
    Limoges, 87042, France
  • Research Site
    Lyon, 69373, France

Showing the first 100 of 214 sites across 20 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Gaitskell K, Rogozinska E, Platt S, Chen Y, Abd El Aziz M, Tattersall A, Morrison J. Angiogenesis inhibitors for the treatment of epithelial ovarian cancer. Cochrane Database Syst Rev. 2023 Apr 18;4(4):CD007930. doi: 10.1002/14651858.CD007930.pub3. PubMed 37185961 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2019 to primary completion in Mar 2025, 74 months.

Results were first posted in Jun 2026, 1 year 2 months after primary completion.

Of 73 industry-sponsored phase 3 interventional studies under Ovarian Neoplasms, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 72. This study's 74 months is above that.

Counting every sponsor, half of 125 studies reached it within 59 months; a quarter within 37 and three quarters within 89.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 15, 2018
First posted
Nov 9, 2018
StartActual
Jan 4, 2019
Primary completionActual
Mar 17, 2025
CompletionEst.
Dec 23, 2026
Results first posted
Jun 9, 2026
Last update
Jul 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03737643
Lead sponsor
AstraZeneca
Collaborators
European Network of Gynaecological Oncological Trial Groups (ENGOT), GOG Foundation, Myriad Genetic Laboratories, Inc.
Responsible party
Sponsor
First posted
Nov 9, 2018
Start date
Jan 4, 2019
Primary completion
Mar 17, 2025
Completion
Dec 23, 2026 (estimated)
Results posted
Jun 9, 2026
Last update
Jul 7, 2026

Study contacts

Philipp Harter
principal investigator · European Network of Gynaecological Oncological Trial Groups (ENGOT)
Carol Aghajanian
principal investigator · GOG

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Durvalumab · Olaparib

Start the discussion